Table 5 Adjusted odds ratios and 95% CI for interactions between injection with a used syringe and the IDU risk network variables.

Number of talwin/ritalin users in IDU risk network

0

7.9 (3.7–16.8)

95 HCV +/58 HCV - (62%)

1.00

24 HCV +/81 HCV - (22.9%)

1–3

0.6 (0.3–42.4)

26 HCV +/10 HCV - (72%)

1.00

16 HCV +/7 HCV - (69.6%)

4–5

1.0 (0.2–156.8)

28 HCV +/9 HCV - (76%)

1.00

9 HCV +/2 HCV - (81.8%)

B)

Reported injection with used syringe

Yes

No

Number of IDU who have shown the respondent how to inject drugs

0

7.9 (3.7–16.8)

111 HCV +/41 HCV - (73.0%)

1.00

36 HCV +/63 HCV - (36.4%)

1

7.7 (0.3–37.1)

31 HCV +/23 HCV - (57.4%)

1.00

8 HCV +/20 HCV - (28.6%)

2–5

0.4 (0.2–87.2)

7 HCV +/13 HCV - (33.3%)

1.00

5 HCV +/7 HCV - (41.6%)